TuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Consensus Rating of “Moderate Buy” from Analysts

TuHURA Biosciences, Inc. (NASDAQ:HURA) has been given an average recommendation of “Moderate Buy” by the six ratings firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $9.00.

HURA has been the subject of several recent research reports. Rodman & Renshaw initiated coverage on shares of TuHURA Biosciences in a research note on Wednesday, April 15th. They set a “buy” rating for the company. Citizens Jmp initiated coverage on shares of TuHURA Biosciences in a research note on Monday, April 27th. They set a “market outperform” rating and a $9.00 target price for the company. Wall Street Zen downgraded shares of TuHURA Biosciences from a “hold” rating to a “sell” rating in a research note on Sunday, May 31st. Citigroup started coverage on shares of TuHURA Biosciences in a research note on Monday, April 27th. They set an “outperform” rating on the stock. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of TuHURA Biosciences in a research report on Tuesday, April 21st.

Institutional Investors Weigh In On TuHURA Biosciences

A number of hedge funds have recently added to or reduced their stakes in HURA. Bank of America Corp DE acquired a new stake in TuHURA Biosciences in the fourth quarter valued at about $59,000. Jane Street Group LLC acquired a new stake in TuHURA Biosciences in the first quarter valued at about $69,000. Geode Capital Management LLC lifted its position in TuHURA Biosciences by 111.4% in the second quarter. Geode Capital Management LLC now owns 582,992 shares of the company’s stock valued at $1,300,000 after purchasing an additional 307,260 shares during the period. JPMorgan Chase & Co. acquired a new stake in TuHURA Biosciences in the second quarter valued at about $27,000. Finally, New York State Common Retirement Fund acquired a new stake in TuHURA Biosciences in the second quarter valued at about $97,000. Institutional investors and hedge funds own 0.62% of the company’s stock.

TuHURA Biosciences Price Performance

NASDAQ HURA opened at $2.23 on Monday. TuHURA Biosciences has a 1 year low of $0.41 and a 1 year high of $3.90. The company has a market capitalization of $141.69 million, a PE ratio of -3.65 and a beta of 0.01. The company has a fifty day moving average of $2.39 and a two-hundred day moving average of $1.65.

TuHURA Biosciences (NASDAQ:HURA) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01). On average, research analysts expect that TuHURA Biosciences will post -0.56 earnings per share for the current year.

TuHURA Biosciences Company Profile

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.